CFO Chris Degnan stated, "UroGen ended 2024 with $241.7 million in cash, cash equivalents, and marketable securities," and ...

Scotiabank initiated coverage of UroGen Pharma (URGN) with an Outperform rating and $23 price target The company is developing a novel ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers ...